Does Zevra Therapeutics have an economic moat?
Not clearly
Zevra Therapeutics earns -29.2% a year on the money invested in it, a return competitors could match.
The numbers behind it
Return on invested capital, average of recent years-29.2%
Return on invested capital, latest year-19.6%
Gross margin84.5%Share of each sale left after production costs
Net margin78.2%
How we decide
A moat shows up in the numbers as high returns that last. We call it likely when the average return on invested capital over recent years is at least 15% and the gross margin at least 40%, and possible from 10%. The numbers can't show where a moat comes from (brand, network, patents), only that one seems to exist.
More questions about Zevra Therapeutics
Data as of Nov 13, 2026.